26 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
American Acne and Rosacea Society Clinical Research Grants
Deadline for submission is December 31, 2013
The American Acne and Rosacea Society (AARS) offers research grants to advance clinical science, while nurturing younger investigators in the field of acne and rosacea. Research projects that are clinical/translational in nature will receive preferential consideration. Up to four (4) clinical research grants will be awarded in 2014 and each grant will not exceed $10,000.
All funds are to be spent within 18 months of receipt of the award. The AARS does not fund projects that are part of the NIH intramural research program or awards to private foundations without an academic affiliation to dermatology.
Eligible Candidates: Dermatology residents and dermatology fellows, and recent graduates (within 5 years) of US dermatology residency are eligible to apply for these research awards. The sponsor (project mentor) of the applicant must be a member of the AARS but may not apply for or be named payee of the grant award.
Proposal: Provide a short discussion of the aims and relevance of the project including sufficient detail for evaluation by the AARS Research Committee. Previously published material may be submitted in support of the application.
Curricula Vitae: Attach a brief biographical sketch of the applicant that should include a recent, relevant bibliography.
Human Subjects: Applications related to research on human subjects must be accompanied by institutional review board approval or submitted prior to the initiation of successful awards.
Animal Studies: Applications that involve research on animals must demonstrate their relevance to clinical dermatology. In addition, they are to be accompanied by a written approval of an appropriate institutional committee or submitted prior to the initiation of successful awards.
Requirements: Within 30 days of completing the approved project, the grantee is required to submit a written report summarizing their research experience and findings. The grantee must also present the work at the AARS annual meeting to be held within two years of funding. If an approved project cannot be completed as originally proposed or in the time limits mandated, the grantee must immediately contact the AARS.
Deadline: The completed application and supporting materials must be received by December 31, 2013. Grant award recipients will be announced at the 2014 AARS Annual Symposium and approved projects will be funded in July 2014.
Request for Proposals: Hematology Oncology Pharmacy Association 2013 Research Award
The HOPA Foundation Board announces the opening of a call for proposals for the 2013 HOPA Foundation Research Award. The HOPA Foundation will fund up to 3 grants based on the stated scope of work. A total of $50,000 in funding is available to be awarded in 2013 through a competitive peer-review process described below.
The individual award is intended to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns with the strategic plan of the HOPA Foundation. Pharmacy practice is broadly defined including areas such as outcomes, surveys, patient safety, standards validation, and translational science applications. Multiple institutions may be involved in the project, and co-PI projects are allowed. The grant is open to all members of HOPA except standing members of the HOPA Foundation and HOPA Board Members.
The HOPA research grants are intended to provide support for projects that are likely to result in facilitating the efforts of hematology/oncology pharmacists to optimize the care of individuals affected by cancer.
The HOPA Foundation Research Grant Review Panel will be chaired by a Foundation Board member; however its composition may vary based on the nature of the proposals received. Members will be comprised of individuals with expertise and familiarity in practice and research.
1. A Letter of Intent (LOI) must be submitted electronically by June 14, 2013 to the attention of Susan Floutsakos at (firstname.lastname@example.org) who will act as the Grant Administrator.
2. The LOIs will be reviewed by members of the HOPA Foundation Research Grant Panel and a decision regarding acceptance for development into a full grant proposal in July 2013. Concepts presented in the LOI that do not address stated objectives and/or criteria of the RFP will be returned and not considered further with a letter of explanation.
3. Submitters of LOIs that are approved for development will be invited to prepare a full grant proposal using the current NIH format. Refer to http://grants.nih.gov/grants/funding/phs398/phs398.html for format. The grant proposals will be due by September 16, 2013. Grant applications must be submitted electronically as a single pdf file to Susan Floutsakos, (email@example.com) the Grant Administrator.
4. The public announcement of the awards will occur in late November 2013. All applicants will receive written feedback regarding review of their application.
1. Funds will be released to the investigator in their entirety, contingent upon Institutional Review Board approval, unless stipulations are placed on the disbursement by the HOPA Foundation Research Panel in its review of the application.
2. The awardee is required to submit a report of progress every six months to the HOPA Foundation Board Chair.
3. The awardee is expected to present the results of their research at the HOPA annual meeting. This presentation is expected to occur no later than two years after the release of the research funds. The results of the study are expected to be submitted for publication in a peer-reviewed biomedical print or online journal. The HOPA Foundation is to be acknowledged in any presentation or publication for its support of the research.
4. There is no provision for indirect costs in this research grant. A travel budget is expected to be included in the proposal to allow the presentation of the results at the HOPA annual meeting. Additional travel funds should be justified in the context of the needs of the project. Capital equipment purchases are not allowed in this grant.
5. All unused funds remaining from the grant 24 months after the disbursement must be returned to HOPA. The investigator may petition the HOPA Foundation for an extension for use of the funds. This request for an extension must be made at least six months before the expiration of the grant.
James Ewing Foundation of the Society of Surgical Oncology and Susan G. Komen for the Cure 2013 Fall Clinical Investigator Award in Breast Cancer Research
Application deadline: Monday, July 8, 2013
Purpose: To promote patient-oriented research conducted by surgical oncologists in clinical and translational science.
Applicants must be surgical oncologists within 10 years of completion of training
Be full SSO members for at least 6 months prior to application submission to be eligible for the award
Applicants must commit to at least 25% effort for this award
Terms of the Award
The award will be funded for two years at $100,000 ($50,000 per year) beginning October 1, 2013. The Award concludes September 30, 2015.
The award is given to the sponsoring institution and may be used for partial support of applicant’s salary, research fellows or staff support, tuition, travel(no more than $2,000 per year) and/or supplies. No additional funds are available for paying indirect costs.
A brief year-one progress report with a financial update will be required by September 30, 2014. The JEF reserves the right to withhold the second year of support in the event of unsatisfactory progress.
A final report (not to exceed 4 pages) will be required before September 30, 2015. This should include a summary of the project, abstracts and publications acknowledged as supported by this award, and a financial report. Any unexpended funds from the scholarship are to be reimbursed back to JEF.
A brief (up to 10 minutes) presentation of results will be required at the March 2-5, 2016, SSO Annual Cancer Symposium in Boston, MA.
The James Ewing Foundation of the Society of Surgical Oncology requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus.
Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group. While the applicant need not be the principal investigator of the trial, nor the lead institutional investigator, the extent to which the applicant is involved in study design and conduct must be clearly articulated. Ideal applicants will be early to mid-career investigators with a track record of peer-reviewed research funding who are seeking additional extramural support to further clinical cancer research. Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers. The track record of the applicant, scientific merit of the application, novelty and clinical impact of the anticipated results, and resources available to ensure completion of the study will comprise the review criteria.
Contact the James Ewing Foundation of the Society of Surgical Oncology, Email: firstname.lastname@example.org, or phone 847-427-1400, ext. 111, M-F, 8:30 a.m. - 4:30 p.m. (CT).Address:9525 W. Bryn Mawr Ave., Suite 870 Rosemont, Illinois 60018. Web: www.surgonc.org
Call for Nominations: Rawls-Palmer Progress in Medicine Award
The Rawls-Palmer Progress in Medicine Award was established in 1978 by Dr. W. B. Rawls to further his commitment to continuing medical education and its impact on patient care. This award was founded through the generosity of the late Dr. and Mrs. W.B. Rawls, and honors the memory of their parents.
The goal of the Rawls-Palmer Progress in Medicine Award is to incorporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care.
The candidate must be an investigator who is actively involved in high-quality clinical pharmacologic research and capable of delivering an engaging, comprehensive lecture on recent developments in clinical pharmacology and therapeutics.
Prize and Presentation
The Rawls-Palmer Progress in Medicine Award is presented at the ASCPT Annual Meeting. The recipient will present a lecture focusing on recent developments in clinical pharmacology. In addition, the recipient will receive a $1,000 honorarium and a plaque. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society.
The nomination deadline is Thursday, June 27, 2013.
To submit a nomination, please complete the online nomination form. Please send CVs, letters of support, and other supporting documents to ASCPT at email@example.com.
Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program
The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions. This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research. These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.
Research Funding Priorities
Eligibility and Requirements
Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.
Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.
A small indirect cost amount between $1,000-$2,000 is allowable.
The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:
-- Etiology and risk factors of cutaneous lymphomas.
-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.
-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.
-- Optimizing therapies for cutaneous lymphomas.
-- Improving quality of life for individuals with cutaneous lymphomas
2013 Calendar of Award Events
January 31 - Public announcement of Request for Application (RFA)
July 31 - Application deadline
August - October - Scientific Review Board review
November - Recipients notified of award
December - Grant awards announced at ASH meeting
January, 2014 - Disbursement of Award and beginning of new award cycle
Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374
ISCTR-American College of Cardiology Foundation Cardiovascular Translational Research Scholarship
sponsored by Dignity Health, St. John's Hospital
The purpose of the program is to recognize and provide financial support for research efforts by outstanding cardiovascular scholars. This scholarship is to encourage junior faculty in the early phases of their careers in the field of cardiology. The program is intended for a physician with a strong interest in developing a career in cardiovascular translational research.
One year of previous interventional cardiology training is required. The duration of the program is one year. The awardee will develop skills and expertise in translating basic biological and device concepts into clinical application.
Goal: The overall goal of the program is to provide the clinical scientist (a physician) with the necessary scientific background that does not exist in today's curriculum. The program will enable the awardee to expedite scientific discovery to clinical application, ultimately benefitting the patient and society by providing science earlier and decreasing the developmental costs related to new devices and/or novel biologic therapies.
The program will cover the topics of:
• Basic science
• Preclinical science
• Clinical science and trial design
• Regulatory pathways (FDA) for IND (investigational new drug application) and IDE (investigational new device exemption)
The emphasis will be on biologics (stem cell therapy and genomics) and cardiovascular device development.
Objectives: The fellow will:
• Develop the skills and knowledge to take a scientific concept to the bedside
• Gain substantial knowledge about the steps in cardiovascular translational research
• Understand product development related to devices or biologics
• Learn about toxicology studies required on small and large animal models that serve for IND or IDE application
• Understand the statistical design and analysis required for toxicology studies, and phase I, II, and III clinical trials
• Learn about the regulatory pathways for and how to prepare an IND (Investigational Drug Application) and an IDE (Investigational Device Exemption)
• Understand fundraising, NIH grant application process, opportunities in the venture capital arena, and developing and maintaining relationships with industry
Eligibility: Applicants eligible for the award are those who:
• Have completed one year of previous interventional cardiology.
• Are members or are eligible to become a member of the ACC and ISCTR
• Will spend the duration of the Scholarship at an institution that has the ability to perform translational research (conducts both preclinical and clinical research) and can administer the curriculum found here:
The Award: The award will offer $60,000 of salary support to begin July 1, 2014 and run through June 30, 2015.
Funding Source: The ACCF is grateful to Dignity Health St. John’s Hospital for their financial support for this award.
Nomination Procedure: Criteria for selection includes qualifications, background, interests, and commitment of the applicant.
How to Apply: The submission site for applications will open this summer. Please stay tuned for more information.
Deadline: September 23, 2013
For more information: Email Julia Berman or call 800-253-4636, ext. 6648.
Call for Applications: Meso Foundation Research Grants
The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:
· Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;
· Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and
· Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.
The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.
Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.
Encouraged projects include, but are not limited to, investigations of:
1. Strategies for early detection of new or progressive disease;
2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;
3. Therapeutic intervention, including but not limited to;
a. Immune Response Targeted Therapy
b. Novel chemotherapeutic compounds
c. Novel radiation or surgical techniques
4. Determination of clinical/molecular determinants for prognosis
Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.
Applications will be evaluated on the following criteria:
Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?
Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.
2013 ASPIRE Rheumatology Research Awards
As competition for research funding increases, the ASPIRE program underscores Pfizer's commitment to supporting research in rheumatologic diseases.
The mission of the 2013 ASPIRE program is to support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.
The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising investigators with an interest in advancing knowledge in defined disease areas including rheumatologic diseases.
Scientific research continues to advance our knowledge and understanding of rheumatologic diseases. The 2013 ASPIRE Rheumatology Research Awards are designed to fund research proposals aimed to further the understanding of certain rheumatologic conditions and contribute to excellence in patient care.
Areas of Focus
Research areas of interest are as follows:
• Biomarker development/validation using patient-derived material
• Studies to improve diagnosis, prognosis or treatment
• Imaging in early diagnosis
• Imaging in treatment monitoring
• Patient-Reported Outcomes
• Impact of Discordance Between Patient and Physician Ratings of Disease Activity on Outcomes
Pfizer is funding research awards up to a maximum of $75,000 USD per-annum for up to 2 years (maximum total of an award over the 2 years of funding is $150,000).
To be eligible for an award, applicants must:
• have a professional degree (MD, PhD, PharmD or equivalent)
• reside in the United States
Deadline for Application
• Applications must be received by July 1, 2013, 11:59pm EDST
• Addenda, supplemental materials, changes, or updates will not be accepted after the deadline
• Notification of Awards recipients will be in August 2013
How to Apply
Applications are to be submitted to Pfizer through an online submission website.
Amyloidosis Foundation 2013 Senior Research Grant
History of the Amyloidosis Foundation: The Amyloidosis Foundation is a result of the merge of the Amyloidosis Research Foundation and the Amyloidosis Support Network in 2007. The ARF’s original mission was to support research for all types of amyloidosis and the ASN’s original mission was to increase awareness of the disease and support patients with information. The new organization maintains both missions with the intent of expanding our services to both patients and the medical and scientific community.
The grant program supports two research areas, basic scientific research and translational research. Applicants will have completed their doctoral studies or clinical fellowship more than ten (10) years prior to application to this program. Although a mentor is not a requirement, the involvement of one will be considered in the feasibility review of the proposal.
Complete applications must be received by August 1, 2013. You will receive a confirmation email or fax from the AF upon receipt of your application.
Selection and Considerations
The selection of the recipient(s) will be made by the Board of Directors of the foundation, after all applications have been reviewed by the Scientific Advisory Board, consisting of experts in the field of amyloidosis. Candidates are strictly prohibited from contacting any members of the advisory board regarding status of their application.
The committee will consider most favorably those proposals that provide evidence of an applicant’s research initiative and creativity. The committee will also consider the feasibility of meaningful results from the proposed research, and the likely contribution to the advancement of knowledge of Amyloidosis etiology, diagnosis, treatment, or prevention.
All candidates will receive notification from the AF office of the final selection of the recipient(s) via email or mail. The award announcement for this grant cycle will be no later than December 1, 2013.
Award Conditions and Reporting
The monetary award of $100,000US will be provided to the awardee's sponsoring institution in two payments of $50,000US for the direct support of the recipients work during the award year, which will begin January 1, 2014. Acknowledgement of receipt of the funds and date of receipt is required of the sponsoring institution.
At the mid point of the year, a brief update report must be submitted to the AF. This report is required prior to the release of the remaining funds. At the conclusion of the award year, the recipient is required to submit a brief written summary of the research conducted.
Recipients are expected to credit the foundation in any publications or presentations that result from the funded research.
Amyloidosis Foundation, Inc.
7151 N. Main St. Suite 2
Clarkston, MI 48346
Amyloidosis Foundation 2013 Junior Research Grant
The grant program supports two research areas, basic scientific research and translational research. Applicants will have completed their doctoral studies or clinical fellowship within ten (10) years prior to application to this program. Although a mentor is not a requirement, the involvement of one will be considered in the feasibility review of the proposal.
The monetary award of $50,000US will be provided to the awardees sponsoring institution in two payments of $25,000US for the direct support of the recipients work during the award year, which will begin January 1, 2014. Acknowledgement of receipt of the funds and date of receipt is required of the sponsoring institution.